• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

The Medicines Company

edit

The Medicines Company is focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. The Company markets Angiomax(R) (bivalirudin) in the United States and other countries for use in patients undergoing coronary angioplasty, and Cleviprex(R) (clevidipine butyrate) injectable emulsion in the United States for the reduction of blood pressure when oral therapy is not feasible or not desirable. The Company also has two products in late stage development: cangrelor, an investigational antiplatelet agent, and oritavancin, a semi-synthetic lipoglycopeptide antibiotic. The Company’s pipeline also includes a serine protease inhibitor, CU2010, in early-stage development.

Recent Milestones

edit

• 
  The Medicines Company acquired Incline Therapeutics. (12/12/12)
  Posted 12/14/12 at 12:15am via marketwire.com
• 
  The Medicines Company acquired ApoA-I Milano for $420M. (12/22/09)
  Posted 1/13/10 at 4:02am via themedicinescompany.com
• 
  The Medicines Company added Christina Willwerth as Sr. Director, Product Development &Director, Clinical Operations &Associate Director, Clinical Operations &Senior Clinical Project Manager .
  Posted 5/2/13 at 1:28pm

Videos

Screenshots

edit

Above: The Medicines Company
Uploaded: 1/13/10

Sources

1. The Medicines Company Agrees to Acquire Incline Therapeutics, Inc. (marketwire.com) [edit]
2. The Medicines Company Acquires ApoA-I Milano From Pfizer (ir.themedicinescompany.com) [edit]